The price of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares last traded on Wall Street rose 2.16% to $41.18.
Based on available information, 4 analysts follow Supernus Pharmaceuticals Inc. (NASDAQ:SUPN). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $47.00 and a low of $38.00, we find $44.00. Given the previous closing price of $40.31, this indicates a potential upside of 9.15 percent. SUPN stock price is now 12.70% away from the 50-day moving average and 26.83% away from the 200-day moving average. The market capitalization of the company currently stands at $2.23B.
Among analysts, 1 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $43.25 as their price target over the next twelve months.
, while ‘Piper Sandler’ rates the stock as ‘Overweight’.
In other news, Khattar Jack A., President, CEO sold 4,936 shares of the company’s stock on Jan 18. The stock was sold for $199,394 at an average price of $40.40. Upon completion of the transaction, the President, CEO now directly owns 794,317 shares in the company, valued at $32.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17, Sr. VP of IP, CSO Bhatt Padmanabh P. sold 4,826 shares of the business’s stock. A total of $192,638 was realized by selling the stock at an average price of $39.92. This leaves the insider owning 1,644 shares of the company worth $67699.92. Insiders disposed of 303,392 shares of company stock worth roughly $12.49 million over the past 1 year. A total of 1.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SUPN stock. A new stake in Supernus Pharmaceuticals Inc. shares was purchased by MESIROW INSTITUTIONAL INVESTMENT MANAGEMENT, INC. during the first quarter worth $13,387,000. TWO SIGMA INVESTMENTS, LP invested $4,244,000 in shares of SUPN during the first quarter. In the first quarter, EAM GLOBAL INVESTORS LLC acquired a new stake in Supernus Pharmaceuticals Inc. valued at approximately $2,120,000. SQUAREPOINT OPS LLC acquired a new stake in SUPN for approximately $1,682,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND purchased a new stake in SUPN valued at around $1,495,000 in the second quarter.
A candlestick chart of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) showed a price of $40.70 on Monday morning. During the past 12 months, Supernus Pharmaceuticals Inc. has had a low of $24.95 and a high of $41.19. As of last week, the company has a debt-to-equity ratio of 0.47, a current ratio of 0.90, and a quick ratio of 0.80. The fifty day moving average price for SUPN is $36.54 and a two-hundred day moving average price translates $32.47 for the stock.
The latest earnings results from Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.56, beating analysts’ expectations of $0.29 by 0.27. This compares to $0.40 EPS in the same period last year. The net profit margin was 5.70% and return on equity was 4.50% for SUPN. The company reported revenue of $177.35 million for the quarter, compared to $148.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.46 percent. For the current quarter, analysts expect SUPN to generate $172.48M in revenue.
Supernus Pharmaceuticals Inc.(SUPN) Company Profile
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson’s disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.